EMA starts assessment of Bavarian Nordic's monkeypox vaccine
The European Medicines Agency (EMA) will investigate whether Imvanex, which is already approved for smallpox, can be authorized within the monkeypox indication.
by christian bundgaard, translated by catherine brett
The EMA has decided to investigate whether Bavarian Nordic’s approved smallpox vaccine Imvanex should also be approved within the monkeypox indication without waiting for an indication expansion application, the authority reveals on its website.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CDC wants children to have access to monkeypox vaccine
For subscribers
